Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics is expected to have a bright future, given its unique approach to developing precision medicines for cancer by targeting individual mutations common in tumors through structure-based and computational drug design. With its lead candidate OKI-345 showing promise in PI3KαH1047R mutated breast cancer, and plans to develop product candidates against additional mutations, the company has strong potential for clinical and commercial success. The recent approval of a competitor's drug in the same market highlights the demand for effective treatments, and OnKure's preclinical data for its pan-mutant PI3Kα inhibitors OKI-345 and OKI-355 indicate they could be best-in-class, further supporting our positive outlook.

Bears say

OnKure Therapeutics is currently a risky investment with a negative outlook due to its limited financial resources and reliance on one operating segment for its revenue. Despite its focus on targeting specific drivers of underserved cancers and its drug design platform, the company has yet to generate significant revenue. Additionally, its current financial metrics, such as low cash and high debt, do not suggest a strong financial position for the company to weather any potential challenges.

OKUR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Buy based on their latest research and market trends.

According to 2 analysts, OKUR has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.